Hanmi Pharm. Co., Ltd.

KOSE:A128940 Stock Report

Market Cap: ₩3.5t

Hanmi Pharm Valuation

Is A128940 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A128940 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A128940 (₩274000) is trading below our estimate of fair value (₩560767.55)

Significantly Below Fair Value: A128940 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A128940?

Key metric: As A128940 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A128940. This is calculated by dividing A128940's market cap by their current earnings.
What is A128940's PE Ratio?
PE Ratio21.6x
Earnings₩160.66b
Market Cap₩3.49t

Price to Earnings Ratio vs Peers

How does A128940's PE Ratio compare to its peers?

The above table shows the PE ratio for A128940 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average61.7x
A237690 ST PharmLtd
53.9x31.6%₩1.8t
A069620 Daewoong Pharmaceutical
13.6x14.0%₩1.4t
A326030 SK Biopharmaceuticals
141.7x50.7%₩8.1t
A214370 Caregen
37.8x25.6%₩1.4t
A128940 Hanmi Pharm
21.6x12.4%₩3.5t

Price-To-Earnings vs Peers: A128940 is good value based on its Price-To-Earnings Ratio (21.6x) compared to the peer average (62.1x).

Price to Earnings Ratio vs Industry

How does A128940's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.3xn/aUS$46.00m
No more companies available in this PE range
A128940 21.6xIndustry Avg. 12.1xNo. of Companies8PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A128940 is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the KR Pharmaceuticals industry average (12.1x).

Price to Earnings Ratio vs Fair Ratio

What is A128940's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A128940 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.6x
Fair PE Ratio21.2x

Price-To-Earnings vs Fair Ratio: A128940 is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the estimated Fair Price-To-Earnings Ratio (21.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A128940 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩274,000.00
₩399,802.77
+45.9%
10.8%₩440,000.00₩290,000.00n/a17
Dec ’25₩272,500.00
₩399,802.77
+46.7%
10.8%₩440,000.00₩290,000.00n/a17
Nov ’25₩306,500.00
₩403,038.06
+31.5%
7.9%₩440,000.00₩324,000.00n/a17
Oct ’25₩321,500.00
₩401,965.40
+25.0%
7.8%₩440,000.00₩324,000.00n/a17
Sep ’25₩315,500.00
₩401,965.40
+27.4%
7.8%₩440,000.00₩324,000.00n/a17
Aug ’25₩295,000.00
₩407,967.32
+38.3%
7.7%₩440,000.00₩324,000.00n/a18
Jul ’25₩285,500.00
₩408,858.62
+43.2%
7.7%₩440,000.00₩324,000.00n/a19
Jun ’25₩283,500.00
₩411,148.15
+45.0%
7.5%₩440,000.00₩324,000.00n/a18
May ’25₩316,500.00
₩407,711.45
+28.8%
7.4%₩440,000.00₩327,758.50n/a20
Apr ’25₩328,000.00
₩407,319.30
+24.2%
7.5%₩440,000.00₩327,758.50n/a20
Mar ’25₩334,000.00
₩407,319.30
+22.0%
7.5%₩440,000.00₩327,758.50n/a20
Feb ’25₩315,500.00
₩397,126.61
+25.9%
7.6%₩440,000.00₩327,758.50n/a19
Jan ’25₩352,500.00
₩378,775.25
+7.5%
7.0%₩421,568.63₩318,627.45n/a18
Dec ’24₩300,490.20
₩377,233.12
+25.5%
7.6%₩411,764.71₩294,117.65₩272,500.0018
Nov ’24₩279,901.96
₩373,223.04
+33.3%
8.1%₩411,764.71₩294,117.65₩306,500.0016
Oct ’24₩293,137.25
₩370,159.31
+26.3%
8.4%₩411,764.71₩294,117.65₩321,500.0016
Sep ’24₩276,960.78
₩370,326.80
+33.7%
8.7%₩411,764.71₩294,117.65₩315,500.0015
Aug ’24₩273,039.22
₩368,014.71
+34.8%
8.8%₩411,764.71₩294,117.65₩295,000.0016
Jul ’24₩302,450.98
₩371,997.55
+23.0%
8.2%₩421,568.63₩319,607.84₩285,500.0016
Jun ’24₩303,921.57
₩371,997.55
+22.4%
8.2%₩421,568.63₩319,607.84₩283,500.0016
May ’24₩316,666.67
₩368,933.82
+16.5%
8.2%₩421,568.63₩319,607.84₩316,500.0016
Apr ’24₩250,980.39
₩338,097.12
+34.7%
8.1%₩382,352.94₩264,705.88₩328,000.0016
Mar ’24₩253,921.57
₩338,563.22
+33.3%
7.9%₩382,352.94₩264,705.88₩334,000.0017
Feb ’24₩257,843.14
₩338,689.18
+31.4%
8.0%₩374,855.82₩264,705.88₩315,500.0018
Jan ’24₩292,156.86
₩337,619.23
+15.6%
7.8%₩374,855.82₩264,321.41₩352,500.0019
Dec ’23₩250,384.47
₩334,942.03
+33.8%
8.2%₩374,855.82₩264,321.41₩300,490.2019

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 11:32
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hanmi Pharm. Co., Ltd. is covered by 32 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dae Woong YooBookook Securities Co. Ltd
Seohyun LeeCitigroup Inc
Hyonseok KimCLSA